Use of a Personalized Clinical Decision Support System for Dosing in Psychopharmacotherapy in Patients with Alcoholic Hallucinosis Based on Pharmacogenomic Markers
Using pharmacogenetic testing to adjust haloperidol dosage improves therapy tolerability and accelerates the resolution of psychotic symptoms in patients with alcoholic hallucinosis, confirming the feasibility of a personalized approach in psychopharmacotherapy.
Authors
- I A Zaytsev
- S. N. Sokolova
- А. Е. Петухов (ORCID: https://orcid.org/0000-0002-4855-4235)
- Sergei Miroshkin (ORCID: https://orcid.org/0000-0003-1058-1657)
- V A Ivanchenko
- S A Pozdniakov
- Valentin Yurievich Skryabin (ORCID: https://orcid.org/0000-0002-4942-8556)
- Dmitry Alekseevich Sychev (ORCID: https://orcid.org/0000-0002-4496-3680)
- Smirnov Vv (ORCID: https://orcid.org/0000-0002-8232-6682)
- I V Bure
Institutions
- Moscow Clinical Scientific Center (RU)
- Moscow Research and Clinical Center for Neuropsychiatry (RU)
- Russian Medical Academy of Continuous Professional Education (RU)
- Research Center of Neurology (RU)
- Federal Medical-Biological Agency (RU)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4511
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00